Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Aurinia Pharmaceuticals Ord Shs (NQ: AUPH)
14.88 USD  -0.37 (-2.43%)
Official Closing Price  /  Updated: 7:57 PM EDT, Jul 10, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 996,300
Open 15.22
Bid (Size) 14.90 (2)
Ask (Size) 14.93 (10)
Prev. Close 15.25
Today's Range 14.80 - 15.34
52wk Range 3.520 - 21.93
Shares Outstanding 84,478,054
Dividend Yield N/A
Performance
YTD
-30.66%
-30.66%
1 Month
+2.13%
+2.13%
3 Month
-3.75%
-3.75%
6 Month
-24.81%
-24.81%
1 Year
+129.63%
+129.63%
Top News
More News
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today... Read More
from Business Wire News Releases
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications,... Read More
from Business Wire News Releases
More News
Read More
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
from Business Wire News Releases
Aurinia Announces Results of Annual General Meeting
from Business Wire News Releases
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
from Business Wire News Releases
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
from Business Wire News Releases
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
from Business Wire News Releases
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
from Business Wire News Releases
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
from Business Wire News Releases
Aurinia Appoints Joe Miller as Chief Financial Officer
from Business Wire News Releases
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.